Immuneering (NASDAQ:IMRX) Given New $10.00 Price Target at Mizuho

Immuneering (NASDAQ:IMRX) had its target price boosted by Mizuho from $8.00 to $10.00 in a research report sent to investors on Wednesday morning,Benzinga reports. The brokerage currently has an outperform rating on the stock.

Several other equities analysts also recently commented on IMRX. Chardan Capital reissued a “buy” rating and set a $13.00 target price on shares of Immuneering in a research report on Wednesday. Oppenheimer lowered their price target on Immuneering from $25.00 to $21.00 and set an “outperform” rating on the stock in a research report on Wednesday, May 7th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $9.00 price target on shares of Immuneering in a research report on Wednesday. One research analyst has rated the stock with a sell rating and four have given a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $13.25.

Immuneering Price Performance

Immuneering stock opened at $2.77 on Wednesday. The company has a market capitalization of $99.69 million, a price-to-earnings ratio of -1.41 and a beta of 0.01. Immuneering has a one year low of $1.00 and a one year high of $3.83. The company’s fifty day moving average price is $1.56 and its two-hundred day moving average price is $1.75.

Immuneering (NASDAQ:IMRX) last posted its earnings results on Monday, May 5th. The company reported ($0.42) EPS for the quarter, missing the consensus estimate of ($0.41) by ($0.01). As a group, sell-side analysts anticipate that Immuneering will post -1.86 earnings per share for the current year.

Insider Activity

In other Immuneering news, Director Thomas J. Schall purchased 40,485 shares of the stock in a transaction dated Tuesday, June 17th. The shares were bought at an average cost of $2.21 per share, with a total value of $89,471.85. Following the completion of the transaction, the director now owns 43,385 shares in the company, valued at $95,880.85. This trade represents a 1,396.03% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 22.90% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Immuneering

A number of institutional investors have recently added to or reduced their stakes in the company. Jane Street Group LLC acquired a new stake in Immuneering during the first quarter worth about $32,000. HighTower Advisors LLC grew its position in Immuneering by 17.7% during the first quarter. HighTower Advisors LLC now owns 83,960 shares of the company’s stock worth $128,000 after buying an additional 12,600 shares in the last quarter. Two Sigma Investments LP grew its position in Immuneering by 25.0% during the fourth quarter. Two Sigma Investments LP now owns 50,557 shares of the company’s stock worth $111,000 after buying an additional 10,126 shares in the last quarter. Tang Capital Management LLC acquired a new stake in Immuneering during the fourth quarter worth about $27,000. Finally, Southport Management L.L.C. grew its position in Immuneering by 4.9% during the fourth quarter. Southport Management L.L.C. now owns 215,000 shares of the company’s stock worth $473,000 after buying an additional 10,000 shares in the last quarter. 67.65% of the stock is owned by institutional investors and hedge funds.

Immuneering Company Profile

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.